| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1999;68:2053-2058
© 1999 The Society of Thoracic Surgeons
a Division of Thoracic Surgery, University of Munich, Munich, Germany
b Department of Surgery, Klinikum Innenstadt, University of Munich, Munich, Germany
c Institute of Immunology, Division of Tumor Immunology, University of Munich, Munich, Germany
Address reprint requests to Dr Passlick, Department of Surgery, University of Munich, Klinikum Innenstadt, Nussbaumstr 20, 80336 Munich, Germany
e-mail: passlick{at}lrz.uni-muenchen.de
Abstract
Background. It recently became evident that isolated tumor cells undetectable by conventional tumor staging are frequently present in bone marrow of patients with apparently localized non-small cell lung cancer (NSCLC). The clinical relevance of this minimal hematogenous tumor cell dissemination is under vigorous debate.
Methods. For tumor cell detection in the bone marrow, we used monoclonal antibody CK2 against the epithelial intermediate filament protein cytokeratin 18. The influence of a positive bone marrow finding on clinical outcome was studied in 139 patients with NSCLC postoperatively staged as pT1–4, pN0–2, M0, and R0 after a median follow-up of 66 months (range 48 to 74 months).
Results. Cytokeratin-18-positive cells in bone marrow were demonstrated in 83 (59.7%) patients at the time of primary surgery and in 6 of 12 representative patients analyzed twice 3 to 18 months after surgery. In patients without histopathological lymph node metastases (pN0; n = 66), the occurrence of 2 or more tumor cells in bone marrow at primary surgery was a strong and independent predictor for overall survival (p = 0.007) in univariate analysis. The multivariate analysis showed a 2.8 times increased risk for shorter survival in patients with disseminated tumor cells versus patients without such cells. Four of the 6 patients with a positive cytokeratin status after surgery developed a tumor recurrence 11 to 44 months after the operation, while none of the patients with a negative bone marrow at all time intervals showed a tumor relapse.
Conclusions. Minimal residual bone marrow involvement is an independent prognostic factor for overall survival in patients with node-negative NSCLC, which may help to identify patients in need of an adjuvant systemic therapy. The postoperative persistence or reappearance of tumor cells in bone marrow indicates that these are not only shedded cells but rather represent true micrometastasis.
Related Article
Ann. Thorac. Surg. 1999 68: 2058.
This article has been cited by other articles:
|
|
 |
|
  A. M. Schwartz and D. E. Henson Diagnostic Surgical Pathology in Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 78S - 93S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Sienel, I. Mecklenburg, S. Dango, P. Ehrhardt, A. Kirschbaum, B. Passlick, and K. Pantel Detection of MAGE-A Transcripts in Bone Marrow Is an Independent Prognostic Factor in Operable Non-Small-Cell Lung Cancer Clin. Cancer Res., July 1, 2007; 13(13): 3840 - 3847. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Prevost, L. Boucher, P. Larivee, R. Boileau, and F. Benard Bone Marrow Hypermetabolism on 18F-FDG PET as a Survival Prognostic Factor in Non-Small Cell Lung Cancer J. Nucl. Med., April 1, 2006; 47(4): 559 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Muller, N. Stahmann, S. Riethdorf, T. Rau, T. Zabel, A. Goetz, F. Janicke, and K. Pantel Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity Clin. Cancer Res., May 15, 2005; 11(10): 3678 - 3685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Doddoli, A. Aragon, F. Barlesi, B. Chetaille, S. Robitail, R. Giudicelli, P. Fuentes, and P. Thomas Does the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer? Eur. J. Cardiothorac. Surg., April 1, 2005; 27(4): 680 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-S. Hofmann, G. Hansen, G. Richter, C. Taege, A. Simm, R.-E. Silber, and S. Burdach Matrix Metalloproteinase-12 Expression Correlates with Local Recurrence and Metastatic Disease in Non-Small Cell Lung Cancer Patients Clin. Cancer Res., February 1, 2005; 11(3): 1086 - 1092. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Mitas, L. Hoover, G. Silvestri, C. Reed, M. Green, A. T. Turrisi, C. Sherman, K. Mikhitarian, D. J. Cole, M. I. Block, et al. Lunx Is a Superior Molecular Marker for Detection of Non-Small Lung Cell Cancer in Peripheral Blood J. Mol. Diagn., November 1, 2003; 5(4): 237 - 242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Marchevsky, J.-H. Qiao, S. Krajisnik, J. M. Mirocha, and R. J. McKenna The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with non-small cell carcinoma of the lung J. Thorac. Cardiovasc. Surg., August 1, 2003; 126(2): 551 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Sienel, R. Seen-Hibler, W. Mutschler, K. Pantel, and B. Passlick Tumour cells in the tumour draining vein of patients with non-small cell lung cancer: detection rate and clinical significance Eur. J. Cardiothorac. Surg., April 1, 2003; 23(4): 451 - 456. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kara, E. Dikmen, D. Kilic, S. Dizbay Sak, D. Orhan, S. K. Kose, and S. Kavukcu Prognostic implications of microscopic proximal bronchial extension in non-small cell lung cancer Ann. Thorac. Surg., August 1, 2002; 74(2): 348 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Jiao and M. J. Krasna Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology Ann. Thorac. Surg., July 1, 2002; 74(1): 278 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sasatomi, S. D. Finkelstein, J. D. Woods, A. Bakker, P. A. Swalsky, J. D. Luketich, H. C. Fernando, and S. A. Yousem Comparison of Accumulated Allele Loss between Primary Tumor and Lymph Node Metastasis in Stage II Non-small Cell Lung Carcinoma: Implications for the Timing of Lymph Node Metastasis and Prognostic Value Cancer Res., May 1, 2002; 62(9): 2681 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Passlick, B. Kubuschock, W. Sienel, O. Thetter, K. Pantel, and J.R. Izbicki Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases -- results of a preliminary study Eur. J. Cardiothorac. Surg., March 1, 2002; 21(3): 520 - 526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Ahrendt, S. C. Yang, L. Wu, C. M. Roig, P. Russell, W. H. Westra, J. Jen, M. V. Brock, R. F. Heitmiller, and D. Sidransky Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer: Preliminary results of a prospective study J. Thorac. Cardiovasc. Surg., March 1, 2002; 123(3): 466 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.J. Poncelet, B. Weynand, F. Ferdin, A.R. Robert, and P.H. Noirhomme Bone marrow micrometastasis might not be a short-term predictor of survival in early stages non-small cell lung carcinoma Eur. J. Cardiothorac. Surg., September 1, 2001; 20(3): 481 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mattioli, F. D'Ovidio, P. Tazzari, V. Pilotti, N. Daddi, G. Bandini, M. Piccioli, and S. Pileri Iliac crest biopsy versus rib segment resection for the detection of bone marrow isolated tumor cells from lung and esophageal cancer Eur. J. Cardiothorac. Surg., May 1, 2001; 19(5): 576 - 579. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
